Status:
COMPLETED
Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment
Lead Sponsor:
Universidad Libre seccional Cali
Collaborating Sponsors:
Immunotec Inc.
Conditions:
COVID-19 (SARS-CoV-2 Infection)
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Abstract Background: Post-COVID-19 cognitive impairment (PCCI), characterized by deficits in attention, memory, and executive functioning, remains a major challenge among patients with long COVID. Oxi...
Detailed Description
Study Design and Participants This randomized, controlled, parallel-group trial included subjects at least 18 years of age in Cali, Colombia, who recovered from COVID-19 infection and presented with m...
Eligibility Criteria
Inclusion
- Inclusion:
- Adults ≥18 years with confirmed prior COVID-19
- with persistent cognitive symptoms
- able to complete testing
- and willing to consent.
- Exclusion:
- Pre-existing dementia or major psychiatric illness
- whey protein allergy - participation in another cognitive trial
- severe hepatic/renal/metabolic disease, pregnancy
- or any condition interfering with participation.
Exclusion
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07184398
Start Date
July 1 2024
End Date
January 1 2025
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Doctor's office
Cali, Valle del Cauca Department, Colombia, 760001